Home / Business and Economy / Weight-Loss Drug Side Effects Spur Product Boom
Weight-Loss Drug Side Effects Spur Product Boom
16 Sep
Summary
- Haleon sees growing sales for products managing GLP-1 drug side effects.
- Products are placed in curated sections and regular aisles at CVS.
- About 11% of Americans are currently using GLP-1 weight-loss drugs.
Consumer health company Haleon has reported a surge in sales for its products addressing the side effects of weight-loss medications in the United States. This growth is directly linked to the increasing popularity of GLP-1 drugs, such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound, which help users lose weight by mimicking appetite-suppressing hormones.
These GLP-1 medications can lead to adverse effects including nausea, vomiting, constipation, and diarrhea. Haleon, known for brands like Advil and Tums, is collaborating with retailers like CVS Pharmacy to offer solutions. Their strategy involves dual placement of products in regular store aisles and specially curated sections for GLP-1 drug users.
This dual placement strategy has resulted in an average 24% sales increase per store, observed in the first quarter of the year. Haleon currently holds a dominant share of GLP-1-related shelf space at CVS, with these dedicated sections outperforming general store placements. The company is also in discussions with Walmart and Target regarding similar in-store strategies. According to analytics firm Gallup, about 11% of Americans are currently taking GLP-1 weight-loss drugs.
